Home > Insider Trading > Filing (0000899243-22-033884)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1521036	Lantheus Holdings Inc.	LNTH	In Vitro & In Vivo Diagnostic Substances (2835)	352318913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1861389	Etienne Montagut	C/O Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica MA 01862	Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-10-18	2,536	$73.41	81,999	No	4	S	Direct
Common Stock	Disposition	2022-10-19	3,324	$71.81	78,675	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The Company requires certain senior executives to cover tax liabilities resulting from the vesting of their equity awards pursuant to sell-to-cover transactions in compliance with Rule 10b5-1. The transaction reported in this Form 4 was effected in compliance with Rule 10b5-1 to satisfy withholding tax liabilities of the Reporting Person associated with the vesting of restricted stock previously granted and reported on a previously filed Form 4.
Includes 345 shares acquired under the LNTH employee stock purchase plan on March 11, 2022 and 215 shares acquired under the LNTH employee stock purchase plan on September 16, 2022.
This transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2022.